Aplicación de hipotermia en extremidades en la prevención de la eritrodisestesia palmo-plantar secundaria a administración de doxorrubicina liposomal pegilada / Applying hypothermia in extremities for the prevention of palmoplantar erythrodysesthesia secondary to the administration of pegylated liposomal doxor

La eritrodisestesia palmo-plantar o síndrome mano-pie es un efecto secundario de algunos tipos de quimioterapia. Se trata de una toxicidad cutánea que no pone en peligro la vida del paciente, pero sí que es dosis limitante y altera la calidad de vida. Se manifiesta en forma de eritema doloroso, a menudo precedido de parestesias en palmas de las manos y plantas de los pies, generando enrojecimiento, hinchazón y dolor, e incluso presencia de flictenas. Para su prevención y control existen medidas farmacológicas, pero también se utiliza la aplicación de crioterapia. Los cuidados de Enfermería son de gran importancia en el manejo de los síntomas, durante el tratamiento y el alivio de los efectos secundarios. El objetivo de este artículo es dar a conocer la eritrodisestesia palmo-plantar, así como aportar la experiencia clínica relacionada con la utilización de crioterapia preventiva mediante un caso clínico

Palmoplantar erythrodysesthesia or hand-foot syndrome is a side effect of some types of chemotherapy. This is skin toxicity not life-threatening for patients, but dose-limiting and with impact on Quality of Life. It appears as a painful erythema, often preceded by paresthesia in hand palms and feet soles, generating reddening, swelling and pain, and even the presence of phlyctenae. There are pharmacological measures for its prevention and control, but the application of cryotherapy can also be used. Nursing care is very important for symptom management, during treatment and relief of side effects. The objective of this article is to create awareness about palmoplantar erythrodysesthesia, as well as to offer the clinical experience associated with the use of preventive cryotherapy through a case report

Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer.

Drug-drug interactions (DDIs) are of great concern in the treatment of cancer, especially when target therapies, such as tyrosine kinase inhibitors, are being used. Here, we report a case of probable DDI between erlotinib and amiodarone leading to severe neurotoxicity. Amiodarone inhibits P-glycoprotein (P-gp), for which erlotinib is a substrate. P-gp is an important drug transporter that is involved in limiting the blood-brain barrier penetration of erlotinib. Clinicians should be aware of emerging data characterizing the effect of the P-gp transport system on drug exposure and its potential for DDI.